Stock listing
BOATS:CNXU Conexeu Sciences Inc. Stock
US listing (BOATS) of Conexeu Sciences Inc. · home listing NASDAQ:CNXU
Follow Conexeu Sciences Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CNXU
$1.55 USD -0.53 (-25.5%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CNXU
- Day range
- $1.48 – $2.09 USDNov 20, 2026
- Volume
- 682,700 sharesNov 20, 2026
- Market cap
- $47.79M USDAt the close on Nov 20, 2026 · price × 30.83M shares outstanding
- Traded on an average day
- $1.14M USDMedian day 234,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CNXU · Home | $1.55 USD | -0.53 (-25.5%) | 682,700 | $2.09 | $2.09 | $1.48 | $2.08 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CNXU · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.55 | -0.53 | -25.5% | $2.09 | $2.09 | $1.48 | 682,700 | |
| $2.08 | -0.28 | -11.9% | $2.38 | $2.57 | $2.01 | 576,700 | |
| $2.36 | +0.36 | +18.0% | $2.08 | $2.36 | $2.00 | 433,100 | |
| $2.00 | -0.21 | -9.5% | $2.23 | $2.40 | $1.97 | 196,400 | |
| $2.21 | +0.03 | +1.4% | $2.19 | $2.21 | $1.95 | 139,900 | |
| $2.18 | 0.00 | 0.0% | $2.19 | $2.30 | $2.05 | 193,000 | |
| $2.18 | -0.08 | -3.5% | $2.22 | $2.39 | $1.93 | 149,300 | |
| $2.26 | +0.04 | +1.8% | $2.26 | $2.45 | $2.22 | 240,200 | |
| $2.22 | -0.11 | -4.7% | $2.29 | $2.30 | $2.01 | 207,200 | |
| $2.33 | +0.07 | +3.1% | $2.29 | $2.40 | $2.19 | 219,800 | |
| $2.26 | +0.14 | +6.6% | $2.11 | $2.34 | $2.10 | 133,100 | |
| $2.12 | -0.10 | -4.5% | $2.19 | $2.30 | $2.07 | 212,000 | |
| $2.22 | -0.16 | -6.7% | $2.38 | $2.40 | $2.12 | 202,100 | |
| $2.38 | -0.02 | -0.8% | $2.38 | $2.45 | $2.23 | 230,600 | |
| $2.40 | -0.14 | -5.5% | $2.70 | $2.75 | $2.26 | 340,000 | |
| $2.54 | -0.29 | -10.2% | $2.85 | $2.85 | $2.43 | 517,300 | |
| $2.83 | -0.05 | -1.7% | $2.94 | $3.07 | $2.79 | 413,700 | |
| $2.88 | -0.07 | -2.4% | $2.92 | $3.00 | $2.78 | 340,200 | |
| $2.95 | +0.01 | +0.3% | $2.96 | $3.00 | $2.83 | 223,400 | |
| $2.94 | -0.16 | -5.2% | $3.13 | $3.15 | $2.90 | 299,700 | |
| $3.10 | -0.20 | -6.1% | $3.22 | $3.30 | $3.08 | 167,300 | |
| $3.30 | -0.03 | -0.9% | $3.28 | $3.45 | $3.06 | 207,600 | |
| $3.33 | +0.34 | +11.4% | $3.05 | $3.59 | $3.00 | 416,700 | |
| $2.99 | -0.30 | -9.1% | $3.33 | $3.60 | $2.95 | 596,800 | |
| $3.29 | +0.23 | +7.5% | $3.27 | $3.35 | $3.05 | 386,400 | |
| $3.06 | -0.89 | -22.5% | $3.96 | $4.00 | $3.05 | 663,900 | |
| $3.95 | +0.30 | +8.2% | $3.66 | $4.05 | $3.40 | 600,300 | |
| $3.65 | +0.34 | +10.3% | $3.44 | $4.36 | $3.42 | 1,147,800 | |
| $3.31 | -0.46 | -12.2% | $3.78 | $3.97 | $3.30 | 284,300 | |
| $3.77 | -0.12 | -3.1% | $4.10 | $4.10 | $3.65 | 362,800 | |
| $3.89 | +0.44 | +12.8% | $3.50 | $4.22 | $3.47 | 427,700 | |
| $3.45 | -0.19 | -5.2% | $3.64 | $3.68 | $3.30 | 243,500 | |
| $3.64 | -0.02 | -0.5% | $3.68 | $3.75 | $3.47 | 239,000 | |
| $3.66 | +0.54 | +17.3% | $3.33 | $3.74 | $3.15 | 328,300 | |
| $3.12 | +0.02 | +0.6% | $3.07 | $3.24 | $3.05 | 171,200 | |
| $3.10 | -0.22 | -6.6% | $3.33 | $3.41 | $3.10 | 114,300 | |
| $3.32 | -0.25 | -7.0% | $3.51 | $3.60 | $3.32 | 95,800 | |
| $3.57 | -0.14 | -3.8% | $3.68 | $3.74 | $3.45 | 194,900 | |
| $3.71 | -0.06 | -1.6% | $3.74 | $3.84 | $3.60 | 241,500 | |
| $3.77 | -0.12 | -3.1% | $3.89 | $3.90 | $3.69 | 179,600 | |
| $3.89 | -0.07 | -1.8% | $4.03 | $4.11 | $3.82 | 111,200 | |
| $3.96 | -0.25 | -5.9% | $4.09 | $4.22 | $3.82 | 163,600 | |
| $4.21 | -0.19 | -4.3% | $4.37 | $4.50 | $3.86 | 235,100 | |
| $4.40 | -0.35 | -7.4% | $4.81 | $4.87 | $4.40 | 158,200 | |
| $4.75 | -0.21 | -4.2% | $5.02 | $5.02 | $4.62 | 138,300 | |
| $4.96 | -0.34 | -6.4% | $5.36 | $5.46 | $4.95 | 608,400 | |
| $5.30 | +0.68 | +14.7% | $4.70 | $5.47 | $4.70 | 233,300 | |
| $4.62 | +0.17 | +3.8% | $4.42 | $4.70 | $4.42 | 114,700 | |
| $4.45 | -0.55 | -11.0% | $5.00 | $5.00 | $4.36 | 124,800 | |
| $5.00 | +0.54 | +12.1% | $4.50 | $5.11 | $4.46 | 191,600 | |
| $4.46 | +0.21 | +4.9% | $4.30 | $4.54 | $4.30 | 114,100 | |
| $4.25 | -0.21 | -4.7% | $4.38 | $4.50 | $4.19 | 166,800 | |
| $4.46 | -0.22 | -4.7% | $4.69 | $4.82 | $4.43 | 191,200 | |
| $4.68 | -0.29 | -5.8% | $4.95 | $4.99 | $4.65 | 276,000 | |
| $4.97 | -0.30 | -5.7% | $5.26 | $5.58 | $4.85 | 249,500 | |
| $5.27 | -0.29 | -5.2% | $5.49 | $5.79 | $5.20 | 305,000 | |
| $5.56 | -0.31 | -5.3% | $5.79 | $6.10 | $5.38 | 224,800 | |
| $5.87 | -1.31 | -18.2% | $7.11 | $7.25 | $5.86 | 352,800 | |
| $7.18 | +0.11 | +1.6% | $7.31 | $7.37 | $6.87 | 189,900 | |
| $7.07 | +0.03 | +0.4% | $7.00 | $7.10 | $6.73 | 176,300 | |
| $7.04 | +0.06 | +0.9% | $7.03 | $7.51 | $6.94 | 227,000 | |
| $6.98 | -0.57 | -7.5% | $7.50 | $7.50 | $6.94 | 290,700 | |
| $7.55 | -0.26 | -3.3% | $7.91 | $8.15 | $7.40 | 321,214 | |
| $7.81 | -1.08 | -12.1% | $8.77 | $9.189 | $7.70 | 411,023 | |
| $8.89 | -0.54 | -5.7% | $9.42 | $10.29 | $8.65 | 395,600 | |
| $9.43 | +0.47 | +5.2% | $8.98 | $9.80 | $8.93 | 261,100 |
- Ticker
- BOATS:CNXU
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Conexeu Sciences Appoints Life Sciences Veteran Daniel M. Bradbury as Chairman of the Board of Directors
Latest deck · 2026
Investor Presentation (2026)
Investor deck · 26 slides
Latest news
Conexeu Sciences Appoints Life Sciences Veteran Daniel M. Bradbury as Chairman of the Board of Directors
Nov 19, 2026
Closed $2.08 (-11.9%) on Nov 19, 2026
Conexeu Sciences Announces Early-Stage Development of W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice, Fabricated Formats of Its Investigational CXU™ Platform
Nov 17, 2026
Closed $2.00 (-9.5%) on Nov 17, 2026
Conexeu Sciences Launches Human Collagen Initiative for Regenerative Aesthetics as GLP-1 Drives Demand for Tissue Restoration
Nov 10, 2026
Closed $2.22 (-4.7%) on Nov 10, 2026
Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors
Oct 15, 2026
Closed $3.06 (-22.5%) on Oct 16, 2026
Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission
Oct 6, 2026
Closed $3.66 (+17.3%) on Oct 6, 2026
Conexeu Sciences Sets September and October 2026 Conference Schedule
Sep 1, 2026
Closed $5.87 (-18.2%) on Sep 1, 2026
Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration
Aug 11, 2026
Closed $7.44 (+2.3%) on Aug 11, 2026
The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It
Jul 14, 2026
Closed $9.50 (-8.1%) on Jul 14, 2026
Initial Statement of Beneficial Ownership (Form 3)
Jun 29, 2026
Closed $10.24 (-6.6%) on Jun 29, 2026
Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform
Jun 25, 2026
Closed $10.22 (-4.4%) on Jun 25, 2026
Conexeu Sciences Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 15 in the last 12 months · 15 in all · newest Nov 19, 2026 · oldest 2026
- Decks
- 1 deck · latest 2026
Where Conexeu Sciences Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CNXU · Home listing | NASDAQ | United States | USD |
| BOATS:CNXU · This page | BOATS | United States | USD |
Valuation
Price/book 8.2× against a median of 1.1×: the highest of 10 Medical devices & supplies companies shown. balance Jul 31, 2026 · price Nov 20, 2026
- Enterprise value
- $45.82M USD
- P/E
- Not reported
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 8.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 2.08
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Conexeu Sciences Inc. · NASDAQ:CNXU | US$47.79M | US$45.82M | n/a | n/a | n/a | 8.2× | n/a | 0.0× | 2.08 |
| Theraclion SA · EURONEXT:ALTHE | US$50.29M | US$49.99M | n/a | 38.4× | n/a | n/a | −479.8% | n/a | n/a |
| Senzime AB · OMXSTO:SEZI | US$49.96M | US$49.20M | n/a | 4.7× | n/a | 2.0× | −92.2% | 0.1× | n/a |
| Hyperfine, Inc. · NASDAQ:HYPR | US$49.73M | US$25.21M | n/a | 1.3× | n/a | 1.6× | −156.4% | 0.4× | 1.67 |
| Modulight Oyj · OMXHEX:MODU | US$48.72M | US$43.29M | n/a | 5.9× | 23.0× | 1.1× | −50.1% | 0.0× | n/a |
| DRTECH Corp. · KRX:214680 | US$48.37M | US$31.72M | n/a | 0.3× | 34.4× | 0.8× | −9.9% | 0.3× | n/a |
| Hironic Co.Ltd · KRX:149980 | US$48.36M | US$32.54M | 14.4× | 1.2× | 6.7× | 0.8× | 12.2% | 0.0× | n/a |
| Venus Medtech (Hangzhou), Inc. Class H · HKEX:2500 | US$48.32M | US$65.50M | n/a | 1.4× | n/a | 0.2× | −132.9% | 0.1× | n/a |
| Medimaging Integrated Solution Inc. · TWSE:6796 | US$48.03M | US$43.05M | 111× | 2.1× | 28.6× | 1.9× | 2.1% | 0.5× | n/a |
| Microbot Medical Inc. · NASDAQ:MBOT | US$45.67M | −US$16.16M | n/a | −38.6× | n/a | 0.7× | n/a | 0.0× | 1.82 |
| RenovoRx, Inc. · NASDAQ:RNXT | US$45.45M | US$35.27M | n/a | 12.7× | n/a | 4.9× | −469.0% | 0.0× | 1.71 |
| Median of the others | US$48.37M | US$39.16M | 62.5× | 1.8× | 25.8× | 1.1× | −92.2% | 0.1× | 1.71 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 20.00 USD · Analysts' mean
- EPS, year to Oct 2026
- -0.40 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Miles D. Harrison | President & Chief Executive Officer |
| Claudia Chavez-Munoz | Co-Founder and Chief Science Officer |
| David Bogart | Chief Commercial Officer and Director |
Board
| Director | Role |
|---|---|
| Daniel M. Bradbury | Chairman of the Board of Directors |
| Aaron Farberg | Director |
| David Bogart | Chief Commercial Officer and Director |
| Jeff Sharpe | Director |
| Sebastian Purcell | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Sep 14, 2026 · After close | −11.0% |
| Q1 2026 | Jul 1, 2026 | −0.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (2026) | Investor deck | 26 slides | 2026 |
Financings
| Raise | Date |
|---|---|
| Private placement of units (and special warrants for certain Canadian subscribers) Closed: US$5M raised · US$3 a unit · 1 warrant at US$3 for 24 months Buyers: Miles Harrison; David Bogart Insiders: Led by existing shareholders including management and directors; $250,000 of subscriptions from certain management and directors held in escrow pending stockholder approval Use of proceeds: Working capital and general corporate purposes, including manufacturing scale-up, regulatory testing and preclinical work for planned FDA 510(k) submission | Oct 15, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-1 · Registration statement | Nov 19, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| D | Nov 5, 2026 | Other filings | SEC |
| D | Nov 5, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Oct 29, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 27, 2026 | Financing | SEC |
| D | Oct 20, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Oct 20, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 20, 2026 | Financing | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
All 92 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| D | Sep 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| D | Sep 15, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Sep 14, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Sep 14, 2026 | Quarterly report | SEC |
| 424B3 · Prospectus | Sep 10, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 10, 2026 | Financing | SEC |
| 4/A · Change in ownership, amended | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Sep 4, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 4, 2026 | Big-stake notice | SEC |
| D | Aug 31, 2026 | Other filings | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 18, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 18, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| D | Jul 30, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 20, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 7, 2026 | Current report | SEC |
| D | Jun 29, 2026 | Other filings | SEC |
| D | Jun 29, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Jun 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 15, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Jun 15, 2026 | Quarterly report | SEC |
| D/A | Jun 12, 2026 | Other filings | SEC |
| D | Jun 10, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 9, 2026 | Financing | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| D | May 21, 2026 | Other filings | SEC |
| D | May 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | May 15, 2026 | Offer document | SEC |
| 8-K · Current report | May 15, 2026 | Financing | SEC |
| 424B3 · Prospectus | May 14, 2026 | Offer document | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | May 12, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | May 11, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 11, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 11, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 11, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 11, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 11, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 11, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 11, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 11, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 11, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 11, 2026 | Insider trade | SEC |
| 424B4 · Prospectus | May 11, 2026 | Offer document | SEC |
| CERT · Exchange's certificate of listing | May 11, 2026 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | May 11, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 17, 2026 | Offer document | SEC |
| S-1/A · Registration statement, amended | Apr 9, 2026 | Offer document | SEC |
| S-1/A · Registration statement, amended | Apr 6, 2026 | Offer document | SEC |
| D | Mar 31, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Mar 26, 2026 | Offer document | SEC |
| D | Mar 20, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Mar 4, 2026 | Offer document | SEC |
| C-AR | Feb 27, 2026 | Other filings | SEC |
| D | Feb 26, 2026 | Other filings | SEC |
| D | Feb 4, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Feb 3, 2026 | Offer document | SEC |
| S-1 · Registration statement | Nov 28, 2025 | Offer document | SEC |
| D | Nov 20, 2025 | Other filings | SEC |
| D | Nov 12, 2025 | Other filings | SEC |
| C-U | Oct 10, 2025 | Other filings | SEC |
| C-U | Sep 23, 2025 | Other filings | SEC |
| C/A | Jul 30, 2025 | Other filings | SEC |
| C | Jul 30, 2025 | Other filings | SEC |
| D/A | Jul 2, 2025 | Other filings | SEC |
| D | Jun 13, 2025 | Other filings | SEC |
| D | May 8, 2025 | Other filings | SEC |
Cap table
Built by 6ix from Conexeu Sciences Inc.’s releases · as of Oct 15, 2026
- Common shares
- 30,831,698
- Fully diluted
- 32,498,365
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 30,831,698 | Oct 15, 2026 |
| Warrants | 1,666,667 | Oct 15, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$3.00 · expire about Oct 2028 |
Share count over time
| Count | Shares |
|---|---|
| Oct 15, 2026 | 30,831,698 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Andrew Costa Other companies: Tigo Energy, Inc. (Co-Chief Operating Officer · Aug 5, 2021 – Apr 25, 2022 · Past) | Director · Since at least Jun 15, 2026 |
| Aaron Farberg | Director · Since at least May 11, 2026 |
| Ana Bastiani-Posner | Director · Since at least Jun 15, 2026 |
| April Burke | Director · Since at least Jun 15, 2026 |
| Brian Keith Pilcher | Chief Medical Officer · Since at least May 11, 2026 |
| Claudia Chavez-Munoz | Chief Science Officer · Since at least May 11, 2026 |
| Daniel M. Bradbury | Chairman of the Board of Directors · Since at least Nov 19, 2026 |
| David Bogart | Chief Commercial Officer, Director · Since at least Sep 25, 2026 |
| Jeff Sharpe | Director · Since at least May 11, 2026 |
| Lynn Sebastian Purcell | Director · Since at least May 11, 2026 |
All 14 people
| Person | Seat |
|---|---|
| Miles D. Harrison | President & Chief Executive Officer · Since at least May 11, 2026 |
| Sebastian Purcell | Director · Since at least Nov 20, 2026 |
| Stephen Douglas Inouye | CFO, Secretary, and Treasurer · Since at least May 11, 2026 |
| Zbigniew Paul Lorenc | Director · Since at least May 11, 2026 |
Log in to ask 6ix AI your own questions about Conexeu Sciences Inc.